[Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
Ursodeoxycholic acid (UDCA) allows symptomatic treatment of cholestatic liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, intrahepatic biliary atresia, and cholestasis of cystic fibrosis. Patients should be treated at an early stage of the disease in order to prevent progression to cirrhosis. Since UDCA has no toxic effects longterm treatment with this substance is possible without the risk of undesired side effects. In patients with primary biliary cirrhosis and rapid progression of the disease, UDCA may be combined with an immunosuppressive substance (i.e. cyclosporin). In primary sclerosing cholangitis, biliary atresia and cholestasis of cystic fibrosis, UDCA at present seems the only treatment of which a benefit for the patients can be expected. In endstage disease liver transplantation is indicated. The role of UDCA in chronic hepatitis and alcohol induced liver disease needs to be clarified in further studies. Whether the improvement of laboratory tests in such patients indicates amelioration of the course of disease, still is unclear.
Stiehl
A
A
Medizinische Universität Heidelberg, Bundesrepublik Deutschland.
D000818:Animals; D001706:Biopsy; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D014580:Ursodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid
Die Behandlung cholestatischer Lebererkrankungen; zur Rolle der Ursodesoxycholsäure.